Yahoo · Oct 14, 2026
2 Beaten-Down Healthcare Stocks That Could Soar in the Fourth Quarter
Both stocks are in negative territory this year, but upcoming earnings reports could change how investors view their prospects.
NASDAQ · DHR
Danaher Corporation
Healthcare · Medical - Diagnostics & Research
$222.84
Up+$1.66 (+0.74%)
Updated Oct 14, 2026, 5:29 PM
SID Score
5.8/10
Composite research score
Smart Money
47/100
Neutral
- Market cap
- 166.5B
- P/E ratio
- 47.14
- Dividend yield
- 0.55%
- 52-week range
- $160.93 – $242.80
- Volume
- 6.01M
- Avg. volume
- 4.18M
Price performance · DHR
DHR price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 13, 2026
DHR closed at $222.84 after 21 trading sessions, up 6.44% for the selected period.
- Last close
- $222.84
- Period change
- +6.44%
- Period low
- $208.36
- Period high
- $227.33
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 13, 2026 | $222.25 | $225.705 | $219.225 | $222.84 | 6.01M |
| Oct 12, 2026 | $220.72 | $221.42 | $219.11 | $221.20 | 3M |
| Oct 9, 2026 | $216.91 | $220.86 | $216.51 | $219.81 | 3.93M |
| Oct 8, 2026 | $217.40 | $218.23 | $211.715 | $217.46 | 5.29M |
| Oct 7, 2026 | $217.77 | $220.48 | $214.39 | $218.49 | 3.97M |
| Oct 6, 2026 | $223.50 | $227.61 | $215.09 | $215.61 | 3.64M |
| Oct 5, 2026 | $213.81 | $222.15 | $213.44 | $221.21 | 3.09M |
| Oct 2, 2026 | $213.40 | $216.0594 | $211.9801 | $214.06 | 3.92M |
| Oct 1, 2026 | $221.31 | $222.00 | $211.18 | $211.76 | 5.3M |
| Sep 30, 2026 | $223.86 | $226.11 | $219.6919 | $221.55 | 5.25M |
| Sep 29, 2026 | $226.19 | $227.65 | $223.505 | $226.11 | 3.61M |
| Sep 28, 2026 | $223.40 | $228.38 | $222.10 | $227.33 | 4.93M |
| Sep 25, 2026 | $223.37 | $224.90 | $221.60 | $224.49 | 4.42M |
| Sep 24, 2026 | $220.50 | $226.65 | $219.00 | $223.77 | 6.2M |
| Sep 23, 2026 | $221.27 | $223.42 | $219.92 | $221.56 | 3.4M |
| Sep 22, 2026 | $215.10 | $222.42 | $214.2801 | $221.09 | 4.64M |
| Sep 21, 2026 | $212.03 | $216.19 | $209.60 | $215.84 | 5.16M |
| Sep 18, 2026 | $212.64 | $214.98 | $210.10 | $211.81 | 8.84M |
| Sep 17, 2026 | $210.48 | $213.27 | $206.6901 | $212.50 | 6.18M |
| Sep 16, 2026 | $209.67 | $211.98 | $206.675 | $208.36 | 3.57M |
| Sep 15, 2026 | $203.08 | $209.55 | $202.6201 | $209.36 | 3.51M |
Latest DHR news
The latest Smart Investors Daily articles mentioning DHR.
Stock researchCompany · Overview
Company
Market Activity
Research & News
DHR research
Overview
Company profile and research snapshot.
Company profile
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $249.71
- Implied upside
- —
- Analysts
- 16
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 13, 2026 | TD Cowen | Buy | — |
| Oct 13, 2026 | Morgan Stanley | Overweight | — |
| Oct 7, 2026 | Barclays | Overweight | — |
| Oct 5, 2026 | RBC Capital | Outperform | — |
| Oct 1, 2026 | Guggenheim | Buy | — |
News briefing
Generated Oct 14, 2026, 3:18 PM
Why Is DHR Moving Slightly Higher Today?
Danaher Corporation edged up 0.16% today as investors digest a mix of positive strategic developments and technical strength. The modest gain reflects cautious optimism around the company's innovation initiatives and board leadership changes, though broader market sentiment remains measured.
Bottom line: Danaher shows mixed signals today with incremental gains supported by strategic positioning in high-growth markets and solid technical setup, but tempered by emerging concerns about valuation and cash flow dynamics. Investors should monitor the NVIDIA partnership's commercialization progress, bioprocess market adoption rates, and board leadership impact, while staying alert to any dividend or capital allocation warnings that prompted inclusion in the cautionary analysis.
Yahoo · Oct 14, 2026
NVIDIA (NVDA) Could Be 18% Undervalued As AI Partnerships Extend Its Reach
NVIDIA (NVDA) is back in focus after London Stock Exchange Group unveiled a partnership using NVIDIA GPUs and cuDF software to power faster analysis of its massive Tick History market data service. Recent deals with LSEG, Danaher and data center partners have arrived during a period where Nvidia’s share price return has cooled in the very short term, with a 7 day share price decline of 4.48%. However, the 30 day and year to date share price returns of 4.69% and 21.01% indicate that momentum...
Yahoo · Oct 14, 2026
Danaher Teams Up With NVIDIA, Aims To Bring Accelerated Computing, Physical AI Into Labs
Danaher CEO Julie Sawyer Montgomery said AI is transforming science, emphasizing the collaboration’s vision for more connected, adaptive and accessible innovation.
ChartMill · Oct 14, 2026
Danaher (NYSE:DHR) Sets Up for Breakout With Strong Technical Ratings
ChartMill: DANAHER (DHR) breakout setup scores Technical Rating 8 and Setup Quality 9. Watch entry above 226.40, stop 211.17, with key levels.
AI research layers
Interpretive context generated from the platform’s current data sources.
Danaher Corporation Stock Performance
Danaher Corporation shares closed at $223.23, reflecting a daily decline of approximately 1.12% per SID market data. Despite the session pullback, DHR has demonstrated positive momentum over recent periods, gaining 9.64% over the past month and 10.98% over the trailing three months. On a year-over-year basis, however, the stock remains down 3.25%, indicating that longer-term recovery is still in progress. Technical indicators present a constructive picture: DHR trades above both its 50-day moving average of $212.08 and its 200-day moving average of $198.00, according to Massive/Polygon data. The 14-day RSI reads 51.4, suggesting neutral momentum without overbought or oversold conditions. The stock's beta of 0.923 indicates slightly lower volatility relative to the broader market. Average daily trading volume stands at approximately 4.18 million shares, supporting adequate liquidity for institutional positioning within this $166.5 billion market-cap healthcare conglomerate.
Danaher Corporation Valuation Analysis
Danaher Corporation currently trades at a price-to-earnings ratio of 47.14, a premium valuation relative to the broader healthcare sector, according to SID market data. The PEG ratio stands at 14.87, suggesting the stock's earnings growth rate does not fully support its elevated P/E multiple at present levels. The price-to-book ratio registers at 3.23, reflecting the market's recognition of Danaher's intangible asset base and proprietary business system. The company offers a modest dividend yield of approximately 0.53%, per SEC filings, consistent with Danaher's historical emphasis on capital redeployment toward acquisitions and organic reinvestment rather than shareholder distributions. With a market capitalization of $166.5 billion, DHR remains one of the largest diversified healthcare and life sciences companies. The valuation metrics collectively indicate that the market is pricing in expectations for sustained long-term earnings expansion, particularly as the bioprocessing end-market recovery progresses through normalization cycles.
Smart Money Activity for DHR
Danaher Corporation's composite smart money score stands at 48 out of 100, registering a neutral signal per SID market data. The institutional component scores a perfect 25 out of 25, reflecting robust institutional ownership and sustained fund-level conviction in the company. In contrast, the insider score is notably lower at 4.9 out of 25, despite a striking imbalance in recent insider transactions: according to SEC Form 4 filings, there have been 20 insider trades over the past 90 days, with 17 classified as purchases versus only 3 sales. This buy-to-sell ratio of nearly 6-to-1 represents a notable concentration of insider purchasing activity. The dark pool activity score registers at 5.0 out of 25, suggesting limited off-exchange block trading interest at current price levels. Congressional trading activity scores 12.8 out of 25, per 13F institutional filings, indicating moderate legislative portfolio exposure. The divergence between strong institutional conviction and the low composite score warrants monitoring as additional filings are disclosed.
Danaher Corporation Earnings Outlook
Danaher Corporation has delivered consecutive earnings beats in its two most recently reported quarters, according to company earnings reports. In the most recent quarter, DHR posted earnings per share of $2.06, exceeding the consensus analyst estimate of $1.94 by $0.12, representing a positive surprise of approximately 6.2%. The prior quarter showed EPS of $1.94 against estimates of $1.84, a $0.10 beat. Looking ahead, analyst estimates project EPS of $1.92 for each of the next two reporting periods, with results expected on October 20 and October 21, respectively. The flat sequential estimates suggest Wall Street anticipates a period of earnings stabilization following the recent outperformance. The modest step-down from the $2.06 and $1.94 reported figures to the $1.92 forward estimates may reflect seasonal dynamics within Danaher's life sciences and diagnostics segments. Continued execution above consensus could serve as a catalyst for valuation reassessment.
Wall Street Analyst Ratings for DHR
Wall Street analyst sentiment on Danaher Corporation remains uniformly positive, with all recent coverage actions reaffirming bullish ratings, per SID consensus data. On October 7, Barclays maintained its Overweight rating on DHR, following RBC Capital's October 5 reiteration of its Outperform stance. Guggenheim reaffirmed its Buy rating on October 1. These three firms also issued confirmatory ratings in late July following the company's earnings report, with both RBC Capital and Guggenheim maintaining Outperform and Buy designations respectively on July 22, according to Wall Street analyst reports. The consistency of these reiterations — five consecutive maintained-or-reiterated positive ratings without any downgrades — signals sustained institutional-level confidence in Danaher's strategic positioning. No analyst in the recent coverage window has shifted to a neutral or negative stance. The clustering of reaffirmations around key catalytic dates, particularly post-earnings periods, underscores that the company's fundamental execution continues to meet or exceed sell-side expectations across multiple coverage firms.
